Please login to the form below

Not currently logged in
Email:
Password:

Elan names new chairman

Elan Corporation has named former GSK vice chairman pharmaceuticals, Robert A Ingram, as chairman effective January 2011

Neuroscience-focused biotechnology company, Elan Corporation, has named former GlaxoSmithKline (GSK) vice chairman pharmaceuticals, Robert A Ingram, as chairman effective January 26, 2011.

Ingram, who was also formerly CEO of Glaxo Wellcome, will succeed Kyran McLaughlin, who announced his intention to step down as non-executive chairman for Ireland-based Elan in April 2010.

Speaking on the announcement, McLaughlin said: "With top level leadership experience at Glaxo Wellcome and GlaxoSmithKline, Bob has a proven track record of successful leadership and a deep understanding of the industry overall. I am proud to be turning over the chairmanship to such a capable and high integrity leader and know that he will make many contributions as the company continues to develop and advance."

Ingram currently serves on several boards of directors already, including Allergan, Edwards Lifesciences Corporation and Valeant Pharmaceuticals. He has also acted as an advisor to GSK CEO, Andrew Witty, since January 2010.

Commenting on his appointment, Ingram said: "I am impressed with the progress [Elan] has made over the past several years in advancing the science, improving its financial performance, and constructing unique and far reaching collaborations which will enable the company to continue to invest in science and innovate within the world of novel therapeutic advances.

"I look forward to working with the board and the management team to deliver long term benefits to science, patients and shareholders."

7th December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics